Table 1.
Ref. | Nerve Injury | Species | Formulation & Dose | Route | Major Assessments | Primary Finding | Proposed Mechanism |
---|---|---|---|---|---|---|---|
[120] | CCI 1 | Mouse | 150 kDa BoNT/A; 15 pg/paw | Intraplantar injection |
Weight bearing; walking track analysis | Normalization of weight bearing; accelerated recovery of SSI 2 | Proliferation of repair Schwann cells |
[32] | Nerve crush | Mouse | 150 kDa BoNT/A; 15 pg in 2 µL saline | Intraneural injection at crush site | Pinch test; CMAP 3; CNAP 4; nerve fiber number and density | Increased rate of regeneration of myelinated nerves | Proliferation of repair Schwann cells; reduced inflammation |
CCI 1 | Mouse | 15 pg in 20 µL saline | Intraplantar injection | ||||
[30] | Transection/repair of femoral nerve | Rat | IncobotulinumtoxinA (Xeomin®); 100 U/mL 5 for 30 min | Incubation of proximal nerve stump | Walking track analysis; histochemical staining |
Marked acceleration in recovery of 6 FBA × SLR index | Preservation of cholinergic input to femoral motor neurons |
[130] | Transection of tibial nerve with and without repair | Rat | AbobotulinumtoxinA (Dysport®); 16 U/kg | Intramuscular injection in contralateral gastrocnemius muscle | Walking track analysis; EMG; axonal density | Accelerated recovery of walking track performance in rats undergoing nerve transection with immediate repair | Adaptation by CNS in response to muscle weakness in contralateral limb |
1 CCI = chronic constriction injury; 2 SSI = sciatic static index; 3 CMAP = compound muscle action potential; 4 CNAP = compound nerve action potential; 5 U = mouse intraperitoneal lethal dose50 (LD50) units; 6 FBA × SLR = foot-base angle × step length ratio.